Salvinorin a and related compounds as therapeutic drugs for psychostimulant-related disorders

Current Drug Abuse Reviews

Volumn 7, Issue 2, 2014, Pages 128-132

  dos Santos, R G ^a   Crippa, J A S ^a,b   Machado de Sousa, J P ^a,b   Hallak, J E C ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b National Institute for Translational Medicine INCT TM   (Brazil)

Author keywords

Hallucinogens; Psychedelics; Psychostimulants; Salvia divinorum; Salvinorin A

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHETAMINE; COCAINE; CORTICOTROPIN; CREATININE; DOPAMINE; ENADOLINE; GLUCOSE; HYDROCORTISONE; LUTEINIZING HORMONE; METHAMPHETAMINE; NALBUPHINE; NITROGEN; SALVINORIN A; TESTOSTERONE; UREA; CLERODANE DERIVATIVE; KAPPA OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT;

ADDICTION; ARTICLE; BEHAVIOR; CLINICAL TRIAL (TOPIC); COGNITION; DELUSION; DEPERSONALIZATION; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG DEPENDENCE; DRUG SAFETY; DRUG TOLERABILITY; EMOTION; EUPHORIA; HALLUCINATION; HEMATOCRIT; HUMAN; MENTAL DISEASE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SALVIA DIVINORUM; SELF CONCEPT; SPATIAL ORIENTATION; AGONISTS; AMPHETAMINE DEPENDENCE; ANIMAL; CHEMISTRY; COCAINE-RELATED DISORDERS; DISEASE MODEL; ISOLATION AND PURIFICATION; METABOLISM; MEXICO; SALVIA;

AMPHETAMINE-RELATED DISORDERS; ANALGESICS, OPIOID; ANIMALS; COCAINE-RELATED DISORDERS; DISEASE MODELS, ANIMAL; DITERPENES, CLERODANE; DOPAMINE; DOPAMINERGIC NEURONS; HUMANS; MEXICO; RECEPTORS, OPIOID, KAPPA; SALVIA;

EID: 84922231744     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/1874473708666150107122741     Document Type: Article

References (54)

1. United Nations Office on Drugs and Crime. World Drug Report (2014). Vienna: United Nations 2014.
2. van Amsterdam J, Pennings E, Brunt T, et al. Physical harm due to chronic substance use. Regul Toxicol Pharmacol 2013; 66: 83-7.
3. Nutt DJ, King LA, Phillips LD, et al. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010; 376: 1558-65.
4. Morgan CJ, Noronha LA, Muetzelfeldt M, et al. Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users. J Psychopharmacol 2013; 27: 497-506.
5. Haile, CN, Mahoney JJ 3rd, Newton TF, et al. Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate. Pharmacol Ther 2012; 134: 260-77.
6. Stoops WW, Rush CR. Agonist replacement for stimulant dependence: a review of clinical research. Curr Pharm Des 2013; 19: 7026-35.
7. Schultes RE, Hofmann A. Plants of the gods: their sacred, healing and hallucinogenic powers. Rochester: Healing Arts Press 1992.
8. Ott J. Pharmacotheon: entheogenic drugs, their plant sources and history. Kennewick: The Natural Products Co. 1993.
9. Diaz JL. Salvia divinorum: a psychopharmacological riddle and a mind-body prospect. Curr Drug Abuse Rev 2013; 6: 43-53.
10. Zawilska JB, Wojcieszak J. Salvia divinorum: from Mazatec medicinal and hallucinogenic plant to emerging recreational drug. Hum Psychopharmacol 2013; 28: 403-12.
11. Casselman I, Nock CJ, Wohlmuth H, et al. From local to global – fifty years of research on Salvia divinorum. J Ethnopharmacol 2014; 151: 768-83.
12. Prisinzano TE. Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sci 2005; 78: 527-31.
13. González D, Riba J, Bouso JC, et al. Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 2006; 85: 157-62.
14. Johnson MW, MacLean KA, Reissig CJ, et al. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 2011; 115: 150-5.
15. Mendelson JE, Coyle JR, Lopez JC, et al. Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, inhumans: a placebo-controlled trial. Psychopharmacology 2011; 214: 933-9.
16. Addy PH. Acute and post-acute behavioral and psychological effects of salvinorin A in humans. Psychopharmacology 2012; 220: 195-204.
17. Ranganathan M, Schnakenberg A, Skosnik PD, et al. Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. Biol Psychiatry 2012; 72: 871-9.
18. MacLean KA, Johnson MW, Reissig CJ, et al. Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology 2013; 226: 381-92.
19. Negus SS, Mello NK, Portoghese PS, et al. Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 1997; 282: 44-55.
20. Shippenberg TS, Rea W. Sensitization to the behavioral effects of cocaine: modulation by dynorphin and κ-opioid receptor agonists. Pharmacol Biochem Behav 1997; 57: 449-55.
21. Heidbreder CA, Schenk S, Partridge B, et al. Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappaopioid receptor agonist. Synapse 1998; 30: 255-62.
22. Mello NK, Negus SS. Effects of kappa opioid agonists on cocaineand food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 1998; 286: 812-24.
23. Negus SS, Mello NK. Effects of kappa opioid agonists on the discriminative stimulus effects of cocaine in rhesus monkeys. Exp Clin Psychopharmacol 1999; 7: 307-17.
24. Schenk S, Partridge B, Shippenberg TS. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology 1999; 144: 339-46.
25. El Daly E, Chefer V, Sandill S, et al. Modulation of the neurotoxic effects of methamphetamine by the selective κ-opioid receptor agonist U69593. J Neurochem 2000; 74: 1553-62.
26. Mello NK, Negus SS. Interactions between kappa opioid agonists and cocaine. Preclinical studies. Ann N Y Acad Sci 2000; 909: 104-32.
27. Powell KR, Holtzman SG. Modulation of the discriminative stimulus effects of d-amphetamine by mu and kappa opioids in squirrel monkeys. Pharmacol Biochem Behav 2000; 65: 43-51.
28. Schenk S, Partridge B, Shippenberg TS. Reinstatement of extinguished drug-taking behavior in rats: effect of the kappaopioid receptor agonist, U69593. Psychopharmacology 2000; 151: 85-90.
29. Vanderschuren LJ, Schoffelmeer AN, Wardeh G, et al. Dissociable effects of the κ-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine. Psychopharmacology 2000; 150: 35-44.
30. Acri JB, Thompson AC, Shippenberg T. Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593. Synapse 2001; 39: 343-50.
31. Schenk S, Partridge B. Effect of the kappa-opioid receptor agonist, U69593, on reinstatement of extinguished amphetamine selfadministration behavior. Pharmacol Biochem Behav 2001; 68: 629-34.
32. Schenk S, Partridge B, Shippenberg TS. Effects of the kappaopioid receptor agonist, U69593, on the development of sensitization and on the maintenance of cocaine self-administration. Neuropsychopharmacology 2001; 24: 441-50.
33. Shippenberg TS, Chefer VI, Zapata A, et al. Modulation of the behavioral and neurochemical effects of psychostimulants by κ- opioid receptor systems. Ann N Y Acad Sci 2001; 937: 50-73.
34. Cosgrove KP, Carroll ME. Effects of bremazocine on selfadministration of smoked cocaine base and orally delivered ethanol, phencyclidine, saccharin, and food in rhesus monkeys: a behavioral economic analysis. J Pharmacol Exp Ther 2002; 301: 993-1002.
35. Bowen CA, Negus SS, Zong R, et al. Effects of mixed-action κ/μ opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology 2003; 28: 1125-39.
36. Chartoff EH, Potter D, Damez-Werno D, et al. Exposure to the selective κ-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats. Neuropsychopharmacology 2008; 33: 2676-87.
37. Gehrke BJ, Chefer VI, Shippenberg TS. Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum. Psychopharmacology 2008; 197: 509-17.
38. Morani AS, Kivell B, Prisinzano TE, et al. Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacol Biochem Behav 2009; 94: 244-9.
39. Rüedi-Bettschen D, Rowlett JK, Spealman RD, et al. Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys: kappa opioid and serotonergic mechanisms. Psychopharmacology 2010; 210: 169-77.
40. Wee S, Koob GF. The role of the dynorphin-κ opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology 2010; 210: 121-35.
41. Potter DN, Damez-Werno D, Carlezon WA Jr., et al. Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity. Biol Psychiatry 2011; 70: 744-53.
42. Prevatt-Smith KM, Lovell KM, Simpson DS, et al. Potential drug abuse therapeutics derived from the hallucinogenic natural product salvinorin A. Medchemcomm 2011; 2: 1217-22.
43. Butelman ER, Yuferov V, Kreek MJ. κ-Opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci 2012; 35: 587-96.
44. Morani AS, Schenk S, Prisinzano TE, et al. A single injection of a novel kappa opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats. Behav Pharmacol 2012; 23: 162-70.
45. Morani AS, Ewald A, Prevatt-Smith KM, et al. The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats. Eur J Pharmacol 2013; 720: 69-76.
46. Smith MA, Cole KT, Iordanou JC, et al. The mu/kappa agonist nalbuphine attenuates sensitization to the behavioral effects of cocaine. Pharmacol Biochem Behav 2013; 104: 40-6.
47. Trifilieff P, Martinez D. Kappa-opioid receptor signaling in the striatum as a potential modulator of dopamine transmission in cocaine dependence. Front Psychiatry 2013; 4: 44.
48. Freeman KB, Naylor JE, Prisinzano TE, et al. Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug selfadministration in monkeys. Psychopharmacology 2014; 231: 2751-8.
49. Kivell BM, Ewald AW, Prisinzano TE. Salvinorin A analogs and other kappa-opioid receptor compounds as treatments for cocaine abuse. Adv Pharmacol 2014; 69: 481-511.
50. Walsh SL, Strain EC, Abreu ME, et al. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology 2001; 157: 151-62.
51. Walsh SL, Geter-Douglas B, Strain EC, et al. Enadoline and butorphanol: evaluation of κ-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J Pharmacol Exp Ther 2001; 299: 147-58.
52. Mello NK, Mendelson JH, Sholar MB, et al. Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men. Neuropsychopharmacology 2005; 30: 618-32.
53. Goletiani NV, Mendelson JH, Sholar MB, et al. Opioid and cocaine combined effect on cocaine-induced changes in HPA and HPG axes hormones in men. Pharmacol Biochem Behav 2009; 91: 526-36.
54. Simonson B, Morani AS, Ewald AW, et al. Pharmacology and antiaddiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A. Br J Pharmacol 2015; 172: 515-31.